10 09, 2020

@10xGenomics buys @CARTANAbio for in situ GX analysis validation

By | September 10th, 2020|Categories: 10X Genomics, Methods and applications, Next-generation sequencing, Single-cell sequencing|0 Comments

CARTANA in situ sequencing was just bought by 10X Genomics for $41.2 million. They provide a complement to the Visium technology that generates beautiful gene expression maps of tissue sections as seen in Fig 1c of a recent bioRxiv report (see below). The method was […]

4 08, 2020

UK COVID diagnostics from @nanopore and @DNANudge

By | August 4th, 2020|Categories: Diagnostics Tech, Methods and applications, Nanopore sequencing, Next-generation sequencing|0 Comments

The UK biotech sector was in the news yesterday morning with two companies and their COVID tests making headlines: Oxford Nanopore and DNANudge. Both are offering rapid testing for COVID-19 in the NHS and in care homes (where they are desperately needed). There is only […]

30 07, 2020

Happy 6th birthday $1000 genome…

By | July 30th, 2020|Categories: Epigenomics, Next-generation sequencing, Other stuff|3 Comments

When I wrote the post about the $1000 genome’s upcoming 5th birthday last Summer I was hoping the Moore’s Law genome graph would restart it’s downward trajectory. That has not happened according to todays look at their graphic. I’m beginning to wonder how long we’ll […]

23 06, 2020

Brain cancer testing without the invasive biopsy from @decarvalho_lab

By | June 23rd, 2020|Categories: Diagnostics Tech, Early detection, Epigenomics|0 Comments

Brain cancer is difficult to diagnose and stratify without an invasive biopsy. Daniel De Carvalho’s group have used their cfChIP-Seq technology to non-invasively diagnose and classify brain tumours, potentially removing the need for surgical tissue biopsies. The power of the assay comes from its use of […]

18 06, 2020

Tumour-informed sequencing to increase the sensitivity of ctDNA liquid biopsy

By | June 18th, 2020|Categories: ctDNA, Diagnostics Tech, MRD|0 Comments

A new paper from Nitzan Rosenfeld’s group at CRUK-CI (my old stomping ground) reports astounding sensitivity for ctDNA liquid biopsy. In “ctDNA monitoring using patient-specific sequencing and integration of variant reads” Jonathan Wan and his co-authors performed whole exome sequencing on tumour biopsies (and PBMCs) […]

5 06, 2020

Avida Biomed: early cancer detection with methylation

By | June 5th, 2020|Categories: Diagnostics Tech, Early detection, Epigenomics, MRD|0 Comments

Avida Biomed are an early startup who have developed a novel targeted methylation sequencing technology: Point-n-Seq, for cancer early-detection. Point-n-Seq uses targeted methylation sequencing, which performs enrichment of target molecules directly from cfDNA before bisulfite conversion and amplification. Target panels are small 1-1000 markers. The […]

4 06, 2020

Is MRD detection really possible with 35x coverage of cfDNA?

By | June 4th, 2020|Categories: Early detection, MRD|2 Comments

Ultra-deep & UMI error-corrected sequencing seemed to be the best tool for early cancer detection and MRD. Early detection is now moving to methylation (e.g. GRAIL’s recent CCGA paper) and now MRD is being challenged – this time by 35x WGS sequencing (it’s also being challenged by methylation but that’s for another post).

[…]

18 03, 2020

A CRISPR diagnostic for Covid-19 from @mammothbiosci

By | March 18th, 2020|Categories: Diagnostics Tech, Other stuff|0 Comments

Mammoth Biosciences, one of the two companies developing CRISPR as a diagnostic tool, submitted a medRxiv preprint showcasing their work on a Covid-19 assay. The SARS-CoV-2 DETECTR assay generate results in 30 minutes from from extracted patient sample RNA. The assay performs simultaneous reverse transcription […]

Load More Posts